PEPFAR's annual planning process is done either at the country (COP) or regional level (ROP).
PEPFAR's programs are implemented through implementing partners who apply for funding based on PEPFAR's published Requests for Applications.
Since 2010, PEPFAR COPs have grouped implementing partners according to an organizational type. We have retroactively applied these classifications to earlier years in the database as well.
Also called "Strategic Areas", these are general areas of HIV programming. Each program area has several corresponding budget codes.
Specific areas of HIV programming. Budget Codes are the lowest level of spending data available.
Expenditure Program Areas track general areas of PEPFAR expenditure.
Expenditure Sub-Program Areas track more specific PEPFAR expenditures.
Object classes provide highly specific ways that implementing partners are spending PEPFAR funds on programming.
Cross-cutting attributions are areas of PEPFAR programming that contribute across several program areas. They contain limited indicative information related to aspects such as human resources, health infrastructure, or key populations programming. However, they represent only a small proportion of the total funds that PEPFAR allocates through the COP process. Additionally, they have changed significantly over the years. As such, analysis and interpretation of these data should be approached carefully. Learn more
Beneficiary Expenditure data identify how PEPFAR programming is targeted at reaching different populations.
Sub-Beneficiary Expenditure data highlight more specific populations targeted for HIV prevention and treatment interventions.
PEPFAR sets targets using the Monitoring, Evaluation, and Reporting (MER) System - documentation for which can be found on PEPFAR's website at https://www.pepfar.gov/reports/guidance/. As with most data on this website, the targets here have been extracted from the COP documents. Targets are for the fiscal year following each COP year, such that selecting 2016 will access targets for FY2017. This feature is currently experimental and should be used for exploratory purposes only at present.
plus ups: Uganda has embarked on a program to increase palliative care services for infants and children. These resources will be used to build the capacity of service providers to provide HIV palliative care services for children. To date no dedicated funding had been provided for pediatric palliative care services
"Part of the resources ($320,000) will be used for a national program to build the capacity of service providers in palliative care services for infants and children. The Expansion of national Pediatric HIV/ AIDS prevention, care and treatment services and training of service providers in the republic of Uganda program in collaboration with the Ministry of Health, Regional Center for Quality of Healthcare and other partners in Pediatric HIV/AIDS palliative care will roll out training in pediatric palliative care through didactic courses, clinical placements, mentor ships, and support supervision. Training will include child counseling, pediatric OI prevention and management, adolescent reproductive health issues in HIV positive children, and TB diagnosis and management. This approach will be used to expand access to pediatric palliative services for all children who are being newly diagnosed with HIV through expanded the National infant testing program. The remaining resources ($280,000) will support pediatric care service delivery including- staffing, pediatric palliative care drugs and supplies as needed at selected health facilities. "
Targets
Target Target Value Not Applicable Number of service outlets/programs providing malaria care and/or referral for HIV-infected clients (diagnosed or presumed) as part of general palliative care Total number of service outlets providing HIV-related palliative care 5 (excluding TB/HIV) Total number of individuals provided with HIV-related palliative care 1,250 (excluding TB/HIV) Total number of individuals trained to provide HIV-related palliative 110 care (excluding TB/HIV)
Table 3.3.06:
